Ss Innovations International, INC 8-K filings

SS Innovations International will restate its financial statements for 2022 and 2023, as well as interim periods, due to accounting errors and a change in auditors.

SS Innovations conducted live and online demonstrations of its SSi Mantra-3 Surgical Robotic System in New York City to media, industry analysts, and the investment community.

SS Innovations International will showcase its new SSi Mantra-3 Surgical Robotic System in New York City next week, offering live demonstrations to media, analysts, and investors.

SS Innovations' SSi Mantra surgical robot has been installed at Baidya & Banskota Hospital in Nepal, marking the first such installation in the country.

SS Innovations has been selected as a finalist in the Outstanding Company category for the Surgical Robotics Industry Awards 2024.

SS Innovations' SSi Mantra Surgical Robotic System has received regulatory approval in Indonesia, marking a significant step in expanding access to robotic surgery in the country.

SS Innovations has engaged BDO as its new auditor, a move aimed at facilitating the company's uplisting to a national securities exchange and reflecting its commitment to transparent financial practices.

SS Innovations' SSi Mantra surgical robotic system has successfully performed 100 cardiac surgeries, marking a significant step in its market expansion and global adoption.

SS Innovations International has dismissed BF Borgers CPA PC as its independent auditor, effective May 13, 2024, following an SEC order barring the firm from practicing before the commission.

SS Innovations successfully performed the first infant pyeloplasty using its SSi Mantra Surgical Robotic System, marking a significant milestone in pediatric robotic surgery.

SS Innovations International reported a successful first quarter of 2024, highlighted by increased sales of their SSi Mantra surgical robotic system and the completion of 1,000 surgeries using the system.

SS Innovations' SSi Mantra Surgical Robotic System successfully performed the world's first mitral valve replacement at the Narayana Institute of Cardiac Sciences in India.

SS Innovations International has raised $2 million through convertible notes and granted a significant stock option to its CEO, Dr. Sudhir Srivastava.

SS Innovations successfully demonstrated its telesurgery platform by performing a remote coronary artery suturing on an animal model during its first Multi-Specialty Robotic Surgical Conference in India.

SS Innovations has filed a pre-submission application with the U.S. FDA for its SSi Mantra surgical robotic system, marking a key step towards potential U.S. market entry.

SS Innovations has partnered with Medikabazaar to distribute its SSi Mantra Surgical Robotic System across India.